BRPI0919165A2 - composição farmacêutica,e, uso de um composto - Google Patents

composição farmacêutica,e, uso de um composto

Info

Publication number: BRPI0919165A2
Authority: BR; Brazil
Prior art keywords: compound; pharmaceutical composition; pharmaceutical; composition
Prior art date: 2008-10-03

Application number

BRPI0919165A

Other languages

English (en)

Inventor

Birgitte Willumsen

Christina Kurre Olsen

Christine Kau

Karina Krøjer Søby

Klaus Peter Hertel

Lone Bruun

René Holm

Original Assignee

Lundbeck & Co As H

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-10-03

Filing date

2009-10-01

Publication date

2015-12-08

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41217546&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0919165(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-10-01 Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H

2015-12-08 Publication of BRPI0919165A2 publication Critical patent/BRPI0919165A2/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Psychiatry (AREA)
Addiction (AREA)
Pain & Pain Management (AREA)
Psychology (AREA)
Anesthesiology (AREA)
Hospice & Palliative Care (AREA)
Inorganic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

BRPI0919165A 2008-10-03 2009-10-01 composição farmacêutica,e, uso de um composto BRPI0919165A2 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
DKPA200801392		2008-10-03
DKPA200900591		2009-05-07
PCT/DK2009/050258 WO2010037398A1 (en)	2008-10-03	2009-10-01	Oral formulation

Publications (1)

Publication Number	Publication Date
BRPI0919165A2 true BRPI0919165A2 (pt)	2015-12-08

Family

ID=41217546

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0919165A BRPI0919165A2 (pt)	2008-10-03	2009-10-01	composição farmacêutica,e, uso de um composto

Country Status (16)

Country	Link
US (1)	US20110178094A1 (pt)
EP (1)	EP2344163A1 (pt)
JP (1)	JP2012504560A (pt)
KR (1)	KR20110081176A (pt)
CN (1)	CN102170884A (pt)
AR (1)	AR073755A1 (pt)
AU (1)	AU2009298264A1 (pt)
BR (1)	BRPI0919165A2 (pt)
CA (1)	CA2732613A1 (pt)
CO (1)	CO6321158A2 (pt)
EA (1)	EA201170512A1 (pt)
IL (1)	IL210235A0 (pt)
MX (1)	MX2011001044A (pt)
NZ (1)	NZ590897A (pt)
WO (1)	WO2010037398A1 (pt)
ZA (1)	ZA201102446B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR101157272B1 (ko)	2003-07-22	2012-06-15	아레나 파마슈티칼스, 인크.	5?ｈｔ2ａ 세로토닌 수용체의 조절자로서 이와 관련된질환의 예방 및 치료에 유용한 디아릴 및 아릴헤테로아릴우레아 유도체
US9084742B2 (en)	2007-12-12	2015-07-21	Axovant Sciences Ltd.	Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-Quinoline
US20110021538A1 (en)	2008-04-02	2011-01-27	Arena Pharmaceuticals, Inc.	Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
EP2285377A1 (en) *	2008-05-07	2011-02-23	H. Lundbeck A/S	Method for treating cognitive deficits
US9126946B2 (en)	2008-10-28	2015-09-08	Arena Pharmaceuticals, Inc.	Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
TWI552751B (zh) *	2011-06-20	2016-10-11	Ｈ朗德貝克公司	投予４－（（１ｒ，３ｓ）－６－氯－３－苯基－二氫茚－１－基）－１，２，２－三甲基－哌及其鹽用於治療精神分裂症的方法
US8575174B2 (en)	2011-06-20	2013-11-05	H. Lundbeck A/S	Deuterated 1-piperazino-3-phenyl-indanes for treatment of schizophrenia
WO2016201373A1 (en)	2015-06-12	2016-12-15	Axovant Sciences Ltd.	Diaryl and arylheteroaryl urea derivatives useful for the prophylaxis and treatment of rem sleep behavior disorder
MX391031B (es)	2015-07-15	2025-03-21	Axovant Sciences Gmbh	Derivados de diaril y arilheteroaril urea como moduladores del receptor de serotonina 5-ht2a útiles para la profilaxis y el tratamiento de alucinaciones asociadas con una enfermedad neurodegenerativa.
WO2020089147A1 (en)	2018-10-29	2020-05-07	H. Lundbeck A/S	Amorphous compounds of formula (i) and amorphous compounds of formula (i) salts
US11535600B2 (en)	2018-12-03	2022-12-27	H. Lundbeck A/S	Prodrugs of 4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1,2,2-trimethylpiperazine and 4-((1R,3S)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1H-inden-1-yl)-2,2-dimethyl-1-(methyl-d3)piperazine

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4031216A (en) *	1974-08-12	1977-06-21	Knoll A.G. Chemische Fabriken	3-(3,4-Dialkoxy-benzyl)-3-methyl-piperazines
NZ196284A (en) *	1980-02-29	1983-12-16	Kefalas As	1-piperazino-3-phenylindane derivatives:pharmaceutical compositions
DE3139970A1 (de) *	1981-10-08	1983-04-28	Boehringer Mannheim Gmbh, 6800 Mannheim	Neue carbonsaeurederivate, verfahren zu ihrer herstellung sowie diese verbindungen enthaltende arzneimittel
US5026853A (en) *	1987-04-01	1991-06-25	Janssen Pharmaceutica N.V.	4-substituted-2(or 3)aminocarbonyl-1-piperazineacetamide
US5466806A (en) *	1989-02-08	1995-11-14	Biochem Pharma Inc.	Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
CA2091204C (en) *	1992-03-11	1997-04-08	Ronald J. Mattson	Antiischemic-piperazinyl and piperidinyl-cyclohexanes
DK55192D0 (da) *	1992-04-28	1992-04-28	Lundbeck & Co As H	1-piperazino-1,2-dihydroindenderivater
CA2132411A1 (en) *	1994-09-19	1996-03-20	Michael Trani	Enzymatic esterification of long-chain racemic acids and alcohols
US6410794B1 (en) *	1994-12-16	2002-06-25	Uop Llc	Process for preparation of pharmaceutically desired chiral tetralone from tetralones
US6455736B1 (en) *	1994-12-16	2002-09-24	Uop Llc	Process for preparation of pharmaceutically desired sertraline and sertraline analogs
US5807897A (en) *	1996-03-01	1998-09-15	Zeneca Limited	Aminotetralin derivative and compositions and method of use thereof
EP1073618B1 (en) *	1998-05-01	2003-12-03	Pfizer Products Inc.	Process for the production of enantiomerically pure or optically enriched sertraline-tetralone using continuous chromatography
IN187170B (pt) *	2000-01-04	2002-02-23	Sun Pharmaceutical Ind Ltd
CA2471715A1 (en) *	2001-12-28	2003-07-17	Teva Pharmaceutical Industries Ltd.	A stable pharmaceutical formulation of paroxetine hydrochloride anhydrous and a process for preparation thereof
MXPA06001838A (es) *	2003-08-18	2006-05-04	Lundbeck & Co As H	Sales de succinato y malonato de la trans-4- ((ir, 3s)-6 -cloro-3- fenilindan -1-il)-1, 2, 2- trimetilpiperazina y su uso como medicamento.
AU2006215956A1 (en) *	2005-02-16	2006-08-24	H. Lundbeck A/S	Tartrate and malate salts of trans-1-((1R,3S)-6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine
TWI376373B (en) *	2005-02-16	2012-11-11	Lundbeck & Co As H	Crystalline base of a pharmaceutical compound
US20100173921A1 (en) *	2006-08-10	2010-07-08	Cipla Limited	Antiretroviral Solid Oral Composition
EP2285377A1 (en) *	2008-05-07	2011-02-23	H. Lundbeck A/S	Method for treating cognitive deficits

2009
- 2009-10-01 JP JP2011529448A patent/JP2012504560A/ja active Pending
- 2009-10-01 US US13/119,846 patent/US20110178094A1/en not_active Abandoned
- 2009-10-01 WO PCT/DK2009/050258 patent/WO2010037398A1/en active Application Filing
- 2009-10-01 KR KR1020117007586A patent/KR20110081176A/ko not_active Withdrawn
- 2009-10-01 CA CA2732613A patent/CA2732613A1/en not_active Abandoned
- 2009-10-01 EA EA201170512A patent/EA201170512A1/ru unknown
- 2009-10-01 NZ NZ590897A patent/NZ590897A/en not_active IP Right Cessation
- 2009-10-01 BR BRPI0919165A patent/BRPI0919165A2/pt not_active Application Discontinuation
- 2009-10-01 EP EP09776299A patent/EP2344163A1/en not_active Withdrawn
- 2009-10-01 AU AU2009298264A patent/AU2009298264A1/en not_active Abandoned
- 2009-10-01 CN CN200980139559XA patent/CN102170884A/zh active Pending
- 2009-10-01 MX MX2011001044A patent/MX2011001044A/es active IP Right Grant
- 2009-10-02 AR ARP090103813A patent/AR073755A1/es unknown
2010
- 2010-12-23 IL IL210235A patent/IL210235A0/en unknown
2011
- 2011-03-29 CO CO11037985A patent/CO6321158A2/es not_active Application Discontinuation
- 2011-04-01 ZA ZA2011/02446A patent/ZA201102446B/en unknown

Also Published As

Publication number	Publication date
ZA201102446B (en)	2012-07-25
WO2010037398A1 (en)	2010-04-08
KR20110081176A (ko)	2011-07-13
MX2011001044A (es)	2011-03-21
AR073755A1 (es)	2010-12-01
EP2344163A1 (en)	2011-07-20
AU2009298264A1 (en)	2010-04-08
IL210235A0 (en)	2011-03-31
JP2012504560A (ja)	2012-02-23
CN102170884A (zh)	2011-08-31
CA2732613A1 (en)	2010-04-08
EA201170512A1 (ru)	2011-08-30
NZ590897A (en)	2012-07-27
US20110178094A1 (en)	2011-07-21
CO6321158A2 (es)	2011-09-20

Publication	Publication Date	Title
BRPI0919942A2 (pt)	2014-12-23	Composto, composição farmacêutica, e, uso de um composto
BRPI0907562A2 (pt)	2017-05-23	composto, composição farmacêutica, e, uso de um composto
BRPI0921375A2 (pt)	2015-12-29	composto, composição farmacêutica, e, uso de um composto
BRPI0810696A2 (pt)	2014-10-21	Composto, composição farmacêutica, e, uso de um composto
BRPI1016219A2 (pt)	2016-04-26	composto, composição farmacêutica, e, uso de um composto
BRPI1008793A2 (pt)	2016-03-08	composto, uso de um composto, e, composição farmacêutica
BRPI0921879A2 (pt)	2018-10-16	composto, composição farmacêutica , e, uso de um composto
BRPI0917579A2 (pt)	2016-10-11	composto, composição farmacêutica, métodos, e, uso de um composto
BRPI1007018A2 (pt)	2016-03-29	composto, composição farmacêutica, e , uso de um composto.
BRPI0810161A2 (pt)	2014-12-30	Composto, preparação farmacêutica, composição farmacêutica, e, uso de um composto
BRPI1008906A2 (pt)	2016-03-15	composto, composição farmacêutica, e, uso de um composto.
BRPI0815709A2 (pt)	2017-06-13	composro, composição farmacêutica, e, uso de um composto.
BRPI0906937A2 (pt)	2016-04-19	composto, composição farmacêutica, e, uso de um composto
BR112013008259A2 (pt)	2017-12-12	composto, composição farmacêutica, e, uso de um composto
BR112013015397A2 (pt)	2016-09-20	composto, composição farmacêutica, e, uso de um composto
BRPI0917001A2 (pt)	2016-02-16	composto, composição farmacêutica, e, uso de um composto ou uma composição farmacêutica
BRPI0915134A2 (pt)	2016-02-16	composto, e, uso de um composto
BRPI0918360A2 (pt)	2017-10-10	composto, composição farmacêutica e usos de um composto
BRPI0812942A2 (pt)	2014-12-16	Composto, composição farmacêutica e uso de um composto
BRPI0810019A2 (pt)	2014-10-14	Composto, composição farmacêutica, e, uso de um composto
BRPI0716171A2 (pt)	2013-09-17	composto, composiÇço farmacÊutica e uso de um composto.
BRPI0821115A2 (pt)	2015-06-16	Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto
BRPI0915473A2 (pt)	2015-11-10	composto, composição farmacêutica, e, uso de um composto
BRPI0918517A2 (pt)	2015-12-01	composto, composição farmacêutica, e, uso de um composto
BRPI0919165A2 (pt)	2015-12-08	composição farmacêutica,e, uso de um composto

Legal Events

Date	Code	Title	Description
2016-04-12	B11A	Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
2016-08-02	B11Y	Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]